Clinical Study

A Phase II Study Of The Selective Braf Kinase Inhibitor Gsk2118436 In Subjects With Advanced Non-Small Cell Lung Cancer And Braf Mutations

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to test the safety of the drug GSK2118436 (dabrafenib) and how well it works. We want to find out what effects, good or bad, it has on people with non-small cell lung cancer. All patients who agree to take part in this study will receive dabrafenib.

Criteria:

To Be Eligible For The Study You Must Have Non-Small Cell Lung Cancer To Be Eligible To Participate.

Keywords:

Cancer, Lung, Braf Mutations, Brf1139287, Nsclc

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.